RT Journal Article
SR Electronic
T1 Longitudinal Case-Control Study of Active and Passive Dense Mammographic Breast Tissue
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.17.24302978
DO 10.1101/2024.02.17.24302978
A1 Kendra Batchelder
A1 Basel White
A1 Christina Cinelli
A1 Amy Harrow
A1 Christine Lary
A1 Andre Khalil
YR 2024
UL http://medrxiv.org/content/early/2024/02/18/2024.02.17.24302978.abstract
AB Mammography is used as secondary prevention for breast cancer. Computer-aided detection and image-based short-term risk estimation were developed to improve the accuracy of mammography. However, most approaches inherently lack the ability to connect observations at the mammography level to observations of cancer onset and progression seen at a smaller scale, which can occur years before imageable cancer and lead to primary prevention. The Hurst exponent (H) can quantify mammographic tissue into regions of dense tissue undergoing active restructuring and regions that remain passive, with amounts of active and passive dense tissue that differ between cancer and controls at diagnosis. A longitudinal retrospective case-control study was conducted to test the hypothesis that differences can be detected before diagnosis and changes could signal developing cancer. Mammograms and reports were collected from 50 patients from Maine Medical Center in 2015 with at least a 5-year screening history. Age-matching patients within 2 years created a primary dataset, and within 5 years, a secondary dataset was created to test for sensitivity. The amount of passive (H ≥ 0.55) and active dense tissue (0.45 < H < 0.55) was calculated for each breast and was predicted by creating a linear mixed-effects model. Cancer status was a predictor for passive (p = 0.036) and active (p = 0.025) dense tissue using the primary dataset. However, when increasing the power, cancer status was a predictor for active dense tissue (p = 0.013), while breast status (p = 0.004), time (p = 0.009), and interaction (p = 0.038) were predictors for passive dense tissue. This suggests active dense tissue is a risk for cancer and passive dense tissue is an indication of developing cancer.Required Key MessagesMammographic dense breast tissue can be separated into regions of active and passive.There is more active dense breast tissue in pathology-confirmed cancer cases than controls.Increases in passive dense tissue in a breast could indicate a developing tumor.Competing Interest StatementKB and AK are co-founders of WAVED Medical LLC.Funding StatementResearch reported in this manuscript was partially supported by National Cancer Institute of the National Institutes of Health under award number R15CA246335. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. KB acknowledges partial financial support from the University of Maine through a Janet Waldron Doctoral Research Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received IRB Approval with Waiver of Informed Consent/Authorization (IRB #4664) from Maine Medical Center (Portland, ME) on September 6, 2015, and was compliant with the Health Insurance Portability and Accountability Act (HIPAA).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe authors will make the data available upon reasonable request.